Record-Breaking Price Performance
On 15 July 2026, Sun Pharmaceutical Industries Ltd’s stock price surged to Rs.1,960, setting a new 52-week and all-time high. This peak price represents a 1.03% gain on the day, outperforming the Sensex, which rose by 0.65%. The stock has demonstrated consistent upward momentum, gaining 1.61% over the past two days and trading within a narrow range of Rs.15.15, signalling steady investor confidence.
The stock’s performance over various time frames further underscores its robust trajectory. Over the past week, it has appreciated by 3.82%, compared to the Sensex’s 1.38%. The one-month return stands at 8.50%, significantly higher than the Sensex’s 1.70%. Over three months, the stock has delivered a remarkable 15.52% gain, while the Sensex declined by 0.71% in the same period.
Year-to-date, Sun Pharma has outperformed the benchmark index by nearly 23 percentage points, delivering a 13.97% return against the Sensex’s negative 8.99%. Its one-year return of 13.45% also contrasts sharply with the Sensex’s 6.07% decline, highlighting the company’s resilience and market leadership.
Long-Term Growth and Market Leadership
Sun Pharmaceutical Industries Ltd is a large-cap company with a market capitalisation of Rs.4,65,507 crores, making it the largest entity in its sector. It accounts for 16.92% of the Pharmaceuticals & Biotechnology sector’s market value and contributes 11.95% of the industry’s annual sales, which total Rs.58,462.04 crores.
The company’s long-term financial performance has been impressive, with net sales growing at an annual compound rate of 11.78% and operating profit expanding at 18.20% over the past five years. This growth has been supported by a strong balance sheet, with the company maintaining a net-debt-free status and an average debt-to-EBITDA ratio of just 0.26, indicating negligible leverage.
Sun Pharma’s return on equity (ROE) averages 15.58%, reflecting efficient utilisation of shareholders’ funds and consistent profitability. The company’s return on capital employed (ROCE) is also robust at 22.23%, underscoring its operational efficiency and capital discipline.
Technical Strength and Market Sentiment
The stock’s technical indicators reinforce its bullish trend. It is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. The overall technical trend is classified as bullish, with key indicators such as MACD and Bollinger Bands signalling positive momentum on both weekly and monthly charts.
Immediate support is identified at Rs.1,547.25, the 52-week low, while resistance levels are noted at Rs.1,878.48 (20-day moving average) and Rs.1,960, the current all-time high. Delivery volumes have increased significantly, with a 29.93% rise over the past month and a 28.07% increase on the latest trading day compared to the five-day average, indicating strong market participation.
Quality and Institutional Confidence
Sun Pharmaceutical Industries Ltd is recognised as an excellent quality company based on its long-term financial metrics. It boasts strong management risk scores, excellent growth, and a solid capital structure. The company’s average EBIT to interest coverage ratio stands at an impressive 52.05x, highlighting its ability to comfortably service interest obligations.
Institutional investors hold 37.04% of the company’s shares, reflecting confidence from well-resourced market participants who typically conduct thorough fundamental analysis. The company’s pledge shares are minimal at 1.42%, further indicating strong governance and shareholder alignment.
Sun Pharma is ranked among the top 1% of companies rated by MarketsMOJO across a universe of over 4,000 stocks, with a Mojo Score of 74.0 and a current Mojo Grade of Buy, upgraded from Hold on 8 June 2026. This upgrade reflects improved market perception and fundamental strength.
Valuation and Dividend Profile
The stock trades at a price-to-earnings (P/E) ratio of 37x and a price-to-book value (P/BV) of 5.57x, indicating a premium valuation relative to its peers. Its enterprise value to EBITDA ratio stands at 24.68x, while the PEG ratio is 4.14x, suggesting that the stock’s price reflects expectations of continued growth despite recent profit moderation.
Sun Pharma offers a dividend yield of 0.82%, with the latest dividend declared at Rs.5 per share and a payout ratio of 35.13%. The ex-dividend date was 7 July 2026. This consistent dividend policy complements the company’s growth profile and provides steady income to shareholders.
Recent Financial Trends
While the company has demonstrated strong price appreciation, its recent quarterly financials show some moderation. Profit before tax (PBT) less other income for the quarter ended March 2026 was Rs.3,092.84 crores, down 13.9% compared to the previous four-quarter average. Similarly, profit after tax (PAT) for the quarter was Rs.2,714.03 crores, a decline of 10.6% relative to the prior four-quarter average.
Despite these short-term fluctuations, the company’s long-term fundamentals remain solid, supported by consistent sales growth, strong profitability ratios, and a net cash position.
Historical Performance Comparison
Sun Pharma’s long-term returns have been notable. Over the past three years, the stock has delivered an 82.77% return, significantly outperforming the Sensex’s 17.41% gain. Over five years, the stock’s appreciation of 186.77% dwarfs the Sensex’s 45.90% rise. However, over a ten-year horizon, the stock’s 154.42% return trails the Sensex’s 178.62%, reflecting varying market cycles and sector dynamics.
Yearly returns have consistently outpaced the broader BSE500 index over the last three annual periods, underscoring the company’s ability to generate sustained shareholder value.
Conclusion
Sun Pharmaceutical Industries Ltd’s attainment of an all-time high price of Rs.1,960 on 15 July 2026 marks a significant milestone in its market journey. The stock’s strong performance is underpinned by robust long-term growth, excellent quality metrics, and a commanding position within the Pharmaceuticals & Biotechnology sector. While recent quarterly profit trends have shown some softness, the company’s overall financial health, institutional backing, and technical strength continue to support its elevated valuation and market standing.
